Applikate Technologies is a technology company.
Applikate Technologies has raised $3.0M across 1 funding round.
Applikate Technologies has raised $3.0M in total across 1 funding round.
Applikate Technologies has raised $3.0M in total across 1 funding round.
Applikate Technologies's investors include 2.12 Angels, 50 Partners, Diaspora Ventures, eFounders, Entrée Capital Ventures, Kima Ventures, #SecretFund, The Refiners, Frederic Montagnon, Mark Casady, Thibaud Elziere.
Applikate Technologies is a hardware and software company developing the first automated histology platform with integrated digital imaging, called CHiMP (Clearing Histology with MultiPhoton Microscopy). It stains and images whole tissue samples without physical slicing, automating the pathology workflow to cut processing time, lower labor and materials costs, improve image quality, and reduce misdiagnosis risk[1][2][3]. The platform serves hospitals, clinics, pathologists, histotechs, and medical researchers by eliminating glass slides, tissue cutting, storage, and rework, delivering direct-to-digital results for faster, cheaper, higher-quality diagnostics—particularly validated for prostate cancer[1][2].
Applikate Technologies was founded in 2013 in New Haven, CT, by Michael Torres and Michael Levene, pioneers in pathology, biomedical engineering, optics, and applied physics[1]. The idea emerged from their publication of an innovative clinical histology approach using unique chemical combinations (like benzyl alcohol/benzyl benzoate clearing) and advanced multiphoton microscopy, addressing longstanding inefficiencies in tissue processing[1][2]. Early traction included key U.S. patents granted for the CHiMP platform, joining the Creative Destruction Lab (CDL) incubator, a published prostate cancer diagnostics study proving viability, a CDL Super Session showcase, an over-subscribed seed round transitioning to Inc. status, and ongoing clinical validation studies[1].
Applikate stands out by reengineering pathology from the ground up, bypassing archaic slide-based processes with a fully automated, non-destructive system. Key advantages include:
Applikate rides the wave of digital pathology transformation, shifting from manual, error-prone slide preparation to AI-ready, automated imaging amid rising demands for faster diagnostics in oncology and beyond[1][2]. Timing aligns with multiphoton microscopy advances and clearing techniques, enabling scalable, high-depth histology that legacy systems can't match, while market forces like labor shortages, rising healthcare costs, and telepathology needs amplify its value[2][3]. By fostering intrinsically digital data for collaboration and AI integration, Applikate influences the ecosystem, potentially reducing global medical errors (a key pathology pain point) and enabling new research in human/animal tissues[1][2].
Applikate is poised for expansion through completed clinical validations, leveraging its seed funding and partnerships (CDL, NIH SEED) to secure broader regulatory approvals and hospital pilots[1][4]. Trends like AI-driven pathology analysis and demand for cost-efficient diagnostics will propel CHiMP adoption, potentially disrupting a market reliant on outdated workflows. Its influence may evolve from niche innovator to paradigm leader, scaling via reagent/hardware sales and software ecosystems—ultimately redefining tissue examination as elegantly automated and accessible as its founders envisioned[1][2].
Applikate Technologies has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Venture Round in August 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2021 | $3.0M Venture Round | 2.12 Angels, 50 Partners, Diaspora Ventures, eFounders, Entrée Capital Ventures, Kima Ventures, #SecretFund, The Refiners, Frederic Montagnon, Mark Casady, Thibaud Elziere |